DBV Technologies: First Quarter 2012 Topline, Scientific Activity and Upcoming Clinical Data

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its first quarter topline and its intense scientific activity and clinical data disclosure schedule for the coming weeks.

Back to news